Translational Vision Science & Technology · Nov 2, 2026
Vascular Retinomics Decodes Panvascular Progression: A Retinal Polyvascular Disease Risk Index
By Ren Y, Jiang L, Li C et al.
PURPOSE: To evaluate whether color fundus photograph-derived vascular retinomics predicts progression from single vascular disease to polyvascular disease. METHODS: This prospective cohort study included UK Biobank participants with baseline single vascular disease and eligible color fundus photographs. Progression was defined as incident involvement of a previously unaffected coronary, cerebrovascular, or peripheral arterial bed. After LASSO-Cox and Boruta feature selection, eight survival-learning algorithms were compared. The best-performing model was refitted to derive the Retinal Polyvascular Disease Risk Index (RPVDRI). Performance was evaluated in the testing cohort and benchmarked against conventional clinical factors and SMART2. RESULTS: Among 2592 participants, 334 progressed during a median follow-up of 11.39 years. A 25-feature vascular retinomic panel was retained, and a gradient boosting machine performed best. In the testing cohort, the RPVDRI showed a graded association with progression after multivariable adjustment (highest vs. lowest tertile: hazard ratio, 1.97; 95% confidence interval, 1.03-3.74; P = 0.040; P for trend = 0.029). The RPVDRI achieved 3-, 5-, and 10-year areas under the curve (AUCs) of 0.636, 0.716, and 0.628, respectively. Adding the RPVDRI to conventional clinical factors improved 5-year AUC by 0.113 (P = 0.002), whereas the corresponding improvement beyond SMART2 was 0.037 (P = 0.466). Shapley additive explanations linked predictions to multidomain features and co-attribution. CONCLUSIONS: The RPVDRI was independently associated with polyvascular disease progression and may complement clinical risk assessment in secondary prevention, particularly in scalable or opportunistic settings where comprehensive clinical information is limited. TRANSLATIONAL RELEVANCE: Fundus-derived vascular retinomics may support precision secondary prevention by noninvasively stratifying residual polyvascular progression risk.